Clinical TrialsEnrollment has been completed and dosing initiated for the sixth dose cohort of ONCT-534, a dual-action androgen receptor inhibitor being tested in advanced prostate cancer patients.
Financial PerformanceOncternal Therapeutics reported a net loss that was narrower than expected, driven by greater-than-expected grant revenue.
Future OutlookONCT-534 is viewed as a potential driver of future upside to forecasts, even though it is not currently included in risk-adjusted revenues.